Can multiparametric MRI replace Roach equations in staging prostate cancer before external beam radiation therapy?
Rossano Girometti1, Marco Andrea Signor2, Martina Pancot1
1Institute of Diagnostic Radiology, Department of Medical and Biological Sciences, University of Udine, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia - via Colugna, 50-33100, Udine, Italy.
European Journal of Radiology
|November 16, 2016
Summary
Roach equations (RE) and multiparametric MRI (mpMRI) show moderate agreement for prostate cancer (PCa) T-staging. mpMRI frequently altered staging and risk assessment, suggesting it is a superior tool for PCa staging before radiation therapy.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Accurate T-staging of prostate cancer (PCa) is crucial for treatment planning.
- Roach equations (RE) are a traditional method for estimating PCa T-stage.
- Multiparametric magnetic resonance imaging (mpMRI) offers detailed anatomical and functional information for cancer assessment.
Purpose of the Study:
- To compare the agreement between RE and mpMRI in assessing the T-stage of PCa.
- To evaluate changes in T-stage and risk category assignment based on mpMRI compared to RE.
- To determine the diagnostic performance of mpMRI for detecting locally advanced (≥T3) PCa.
Main Methods:
- Prospective mpMRI acquisition in 73 PCa patients before external beam radiation therapy (EBRT).
- Assessment of agreement using Cohen's kappa statistic for T-stage (≥T3 vs. T≤2) and risk category (National Comprehensive Cancer Network criteria).
- Validation of mpMRI's sensitivity and specificity for ≥T3 stage in 37 patients with post-prostatectomy histology.
Main Results:
- Moderate agreement observed between RE and mpMRI for T-stage (k=0.53) and risk category (k=0.56).
- mpMRI altered T-stage and risk category in approximately 21% of patients, predominantly downstaging PCa compared to RE.
- mpMRI demonstrated high sensitivity (81.8%) and specificity (88.5%) for detecting ≥T3 stage in the validation group.
Conclusions:
- RE and mpMRI exhibit only moderate agreement in PCa T-staging.
- mpMRI leads to a change in risk assessment for about one-fifth of patients, often downstaging the cancer.
- High sensitivity and specificity support mpMRI's utility as a preferred tool for pre-treatment PCa staging before EBRT.


